Alimera: ILUVIEN® Reduced Need for Diabetic Macular Edema Multiple Treatments

 Data from the Phase 4 observational real-world safety study of the intravitreal implant were presented at the annual American Academy of Ophthalmology (AAO) conference.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that post-hoc analyses from the PALADIN Phase 4 Safety Study demonstrate that median treatment frequency in diabetic macular edema (DME) patients treated with the ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg was lower than from patients on other regimens. ILUVIEN provides DME patients with continuous therapy for up to 36 months. As part of the PALADIN phase 4 study, investigators sought to quantify the treatments required by eyes prior to ILUVIEN and after injection of ILUVIEN.

https://finance.yahoo.com/news/paladin-phase-4-study-confirms-120000648.html